Clinical experiment designed to assess clinical efficacy targeting ID in human. Primary outcome: Validate Stress Granule Dysfunction Validation in Parkinson's Disease
Description
Stress Granule Dysfunction Validation in Parkinson's Disease
Background and Rationale
Stress granules are ribonucleoprotein complexes that form during cellular stress to protect mRNAs and regulate translation. Recent evidence suggests that stress granule dysfunction may contribute to alpha-synuclein aggregation and neurodegeneration in Parkinson's Disease (PD). Alpha-synuclein, the primary component of Lewy bodies in PD, can interact with stress granule proteins and potentially disrupt their normal dynamics. This clinical validation study employs a multi-phase approach combining postmortem brain tissue analysis, patient biofluid examination, and induced pluripotent stem cell (iPSC)-derived dopaminergic neurons from PD patients. The study will quantify stress granule markers, assess alpha-synuclein co-localization, and evaluate stress granule dynamics under oxidative stress conditions. Key measurements include immunofluorescence quantification of stress granule proteins (G3BP1, TIA1, PABP1), alpha-synuclein aggregation kinetics, and RNA sequencing of stress granule-associated transcripts....
Stress Granule Dysfunction Validation in Parkinson's Disease
Background and Rationale
Stress granules are ribonucleoprotein complexes that form during cellular stress to protect mRNAs and regulate translation. Recent evidence suggests that stress granule dysfunction may contribute to alpha-synuclein aggregation and neurodegeneration in Parkinson's Disease (PD). Alpha-synuclein, the primary component of Lewy bodies in PD, can interact with stress granule proteins and potentially disrupt their normal dynamics. This clinical validation study employs a multi-phase approach combining postmortem brain tissue analysis, patient biofluid examination, and induced pluripotent stem cell (iPSC)-derived dopaminergic neurons from PD patients. The study will quantify stress granule markers, assess alpha-synuclein co-localization, and evaluate stress granule dynamics under oxidative stress conditions. Key measurements include immunofluorescence quantification of stress granule proteins (G3BP1, TIA1, PABP1), alpha-synuclein aggregation kinetics, and RNA sequencing of stress granule-associated transcripts. The innovation lies in translating preclinical stress granule research to human clinical validation, potentially identifying novel biomarkers and therapeutic targets. This research could reveal stress granule modulation as a disease-modifying strategy for PD, representing a paradigm shift from symptomatic treatment to addressing fundamental cellular dysfunction mechanisms.
This experiment directly tests predictions arising from the following hypotheses:
Phase 1 (Months 1-6): Recruit 50 PD patients and 25 age-matched controls. Collect CSF and plasma samples via standardized protocols. Extract postmortem substantia nigra tissue from 20 PD cases and 15 controls from brain banks. Phase 2 (Months 7-12): Perform immunofluorescence staining for stress granule markers (G3BP1, TIA1, PABP1) and alpha-synuclein in tissue sections using confocal microscopy. Quantify co-localization using Pearson correlation coefficients. Phase 3 (Months 13-18): Generate iPSC-derived dopaminergic neurons from 15 PD patients and 10 controls. Induce oxidative stress using 200μM sodium arsenite for 1-4 hours. Monitor stress granule formation and dissolution kinetics using live-cell imaging. Phase 4 (Months 19-24): Measure stress granule proteins and alpha-synuclein in patient biofluids using ELISA and Simoa platforms. Perform RNA sequencing on stress granule-enriched fractions from iPSC neurons to identify dysregulated transcripts. Statistical analysis using ANOVA with Bonferroni correction for multiple comparisons, with significance set at p<0.05.
Expected Outcomes
1. Increased stress granule protein expression (G3BP1, TIA1) by 2.5-3.5 fold in PD postmortem brain tissue compared to controls (p<0.001)
2. Enhanced co-localization between alpha-synuclein and stress granule markers with Pearson correlation coefficients >0.6 in PD samples vs <0.3 in controls
3. Delayed stress granule dissolution kinetics in PD iPSC neurons, with 50-70% persistence at 2 hours post-stress vs 10-20% in controls
4. Elevated CSF levels of G3BP1 and TIA1 proteins by 1.8-2.2 fold in PD patients compared to healthy controls (p<0.01)
5. Identification of 150-300 differentially expressed transcripts in stress granule fractions from PD neurons, enriched for neurodegeneration pathways
6. Correlation between stress granule dysfunction severity and clinical UPDRS motor scores (r=0.4-0.6, p<0.05)
Success Criteria
• Demonstrate statistically significant increase (p<0.01) in stress granule protein levels in ≥2 different PD sample types compared to controls
• Achieve co-localization coefficients >0.5 between alpha-synuclein and stress granule markers in ≥60% of PD tissue samples
• Establish measurable differences in stress granule dynamics with effect size >0.8 between PD and control iPSC neurons
• Identify ≥100 significantly dysregulated transcripts (FDR<0.05) in PD stress granule fractions with pathway enrichment p<0.001
• Validate ≥2 stress granule biomarkers in patient biofluids with AUC >0.75 for PD discrimination
• Recruit and complete analysis for ≥80% of target sample sizes across all study phases within timeline
TARGET GENE
ID
MODEL SYSTEM
human
ESTIMATED COST
$5,460,000
TIMELINE
45 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Stress Granule Dysfunction Validation in Parkinson's Disease
Phase 1 (Months 1-6): Recruit 50 PD patients and 25 age-matched controls. Collect CSF and plasma samples via standardized protocols. Extract postmortem substantia nigra tissue from 20 PD cases and 15 controls from brain banks. Phase 2 (Months 7-12): Perform immunofluorescence staining for stress granule markers (G3BP1, TIA1, PABP1) and alpha-synuclein in tissue sections using confocal microscopy. Quantify co-localization using Pearson correlation coefficients. Phase 3 (Months 13-18): Generate iPSC-derived dopaminergic neurons from 15 PD patients and 10 controls. Induce oxidative stress using 200μM sodium arsenite for 1-4 hours. Monitor stress granule formation and dissolution kinetics using live-cell imaging.
...
Phase 1 (Months 1-6): Recruit 50 PD patients and 25 age-matched controls. Collect CSF and plasma samples via standardized protocols. Extract postmortem substantia nigra tissue from 20 PD cases and 15 controls from brain banks. Phase 2 (Months 7-12): Perform immunofluorescence staining for stress granule markers (G3BP1, TIA1, PABP1) and alpha-synuclein in tissue sections using confocal microscopy. Quantify co-localization using Pearson correlation coefficients. Phase 3 (Months 13-18): Generate iPSC-derived dopaminergic neurons from 15 PD patients and 10 controls. Induce oxidative stress using 200μM sodium arsenite for 1-4 hours. Monitor stress granule formation and dissolution kinetics using live-cell imaging. Phase 4 (Months 19-24): Measure stress granule proteins and alpha-synuclein in patient biofluids using ELISA and Simoa platforms. Perform RNA sequencing on stress granule-enriched fractions from iPSC neurons to identify dysregulated transcripts. Statistical analysis using ANOVA with Bonferroni correction for multiple comparisons, with significance set at p<0.05.
Expected Outcomes
1. Increased stress granule protein expression (G3BP1, TIA1) by 2.5-3.5 fold in PD postmortem brain tissue compared to controls (p<0.001)
2. Enhanced co-localization between alpha-synuclein and stress granule markers with Pearson correlation coefficients >0.6 in PD samples vs <0.3 in controls
3. Delayed stress granule dissolution kinetics in PD iPSC neurons, with 50-70% persistence at 2 hours post-stress vs 10-20% in controls
4. Elevated CSF levels of G3BP1 and TIA1 proteins by 1.8-2.2 fold in PD patients compared to healthy controls (p<0.01)
5.
...
1. Increased stress granule protein expression (G3BP1, TIA1) by 2.5-3.5 fold in PD postmortem brain tissue compared to controls (p<0.001)
2. Enhanced co-localization between alpha-synuclein and stress granule markers with Pearson correlation coefficients >0.6 in PD samples vs <0.3 in controls
3. Delayed stress granule dissolution kinetics in PD iPSC neurons, with 50-70% persistence at 2 hours post-stress vs 10-20% in controls
4. Elevated CSF levels of G3BP1 and TIA1 proteins by 1.8-2.2 fold in PD patients compared to healthy controls (p<0.01)
5. Identification of 150-300 differentially expressed transcripts in stress granule fractions from PD neurons, enriched for neurodegeneration pathways
6. Correlation between stress granule dysfunction severity and clinical UPDRS motor scores (r=0.4-0.6, p<0.05)
Success Criteria
• Demonstrate statistically significant increase (p<0.01) in stress granule protein levels in ≥2 different PD sample types compared to controls
• Achieve co-localization coefficients >0.5 between alpha-synuclein and stress granule markers in ≥60% of PD tissue samples
• Establish measurable differences in stress granule dynamics with effect size >0.8 between PD and control iPSC neurons
• Identify ≥100 significantly dysregulated transcripts (FDR<0.05) in PD stress granule fractions with pathway enrichment p<0.001
• Validate ≥2 stress granule biomarkers in patient biofluids with AUC >0.7
...
• Demonstrate statistically significant increase (p<0.01) in stress granule protein levels in ≥2 different PD sample types compared to controls
• Achieve co-localization coefficients >0.5 between alpha-synuclein and stress granule markers in ≥60% of PD tissue samples
• Establish measurable differences in stress granule dynamics with effect size >0.8 between PD and control iPSC neurons
• Identify ≥100 significantly dysregulated transcripts (FDR<0.05) in PD stress granule fractions with pathway enrichment p<0.001
• Validate ≥2 stress granule biomarkers in patient biofluids with AUC >0.75 for PD discrimination
• Recruit and complete analysis for ≥80% of target sample sizes across all study phases within timeline